An observational study in Peripheral Arterial Disease (PAD), Ankle Brachial Index and Diagnostic Accuracy, sponsored by Hull University Teaching Hospitals NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Hull University Teaching Hospitals NHS Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Peripheral Arterial Disease with a site in United Kingdom — 20 open to participants now, 24 under way, 5 of them phase 3. Peripheral Arterial Disease · United Kingdom.
Among the 82 studies in Peripheral Arterial Disease with a site in United Kingdom, this one is the 17th largest by planned enrollment of the 31 observational ones that give a count, is one of 4 that started in 2026, is one of 31 observational ones, reaches primary completion later than 16 of the 23 other live ones, and was the 81st registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →20 of the 82 studies in Peripheral Arterial Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Cardiovascular and Interventional Radiological Society of Europe · Sites in United Kingdom
Ages 18+
Cardiovascular and Interventional Radiological Society of Europe · Sites in United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in United Kingdom, United States, Japan
Ages 18+
Eli Lilly and Company · Sites in United Kingdom, United States, Argentina and 15 more countries
Ages 18+
University of Edinburgh · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 13 · Phase 4 2
First in 1997; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 70 across the 51 interventional studies, 420 across the 31 observational. Of the 49 that completed or were terminated, 13 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 82 have an industry lead sponsor. The 10 most frequent:
Hull University Teaching Hospitals NHS Trust is the lead sponsor of 95 studies on the registry; 15 are open to participants now.
Hull University Teaching Hospitals NHS Trust has 3 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Peripheral Arterial Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06827691Manchester Metropolitan UniversityHeat Therapy and Peripheral Artery Disease | 2027-11-20 |
Add it to your calendar (.ics) → With an account.
Among the 82 studies in Peripheral Arterial Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this pilot study is to investigate the diagnostic accuracy of two automated ABPI devices across the spectrum of PAD (asymptomatic PAD, suspected symptomatic PAD [IC; including mild moderate and severe IC based on the Rutherford classification (21) and CLTI] and post-bypass surveillance). A second aim is to assess their useability and tolerability through semi-structured interviews with patients and clinicians. This means the research will be split into two workstreams.
Group 1: Asymptomatic PAD:
Patients identified by the GP (PIC sites). Records screened to identify 'at risk' of PAD with >1 cardiovascular disease risk factor
Group 2: Suspected symptomatic PAD:
2a. Patients with suspected IC referred to dedicated nurse-led claudication clinic.
Group 2b. Patients with suspected CLTI referred to dedicated urgent vascular (HOT) clinic.
Group 3: Patients undergoing surveillance seen in dedicated clinics by vascular scientists
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 1: Asymptomatic
Group 2a: Suspected PAD (intermittent claudication)
Group 2b: Suspected PAD (CLTI)
Group 3: Post-bypass surveillance
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with one or more CVD risk factors
Device: MESI mTablet · Device: BlueDop vascular Expert (BlueDopVE)
Partcipants presenting with Suspected PAD (intermittent claudication)
Device: MESI mTablet · Device: BlueDop vascular Expert (BlueDopVE)
Participants presenting with tissue loss or rest pain
Device: MESI mTablet · Device: BlueDop vascular Expert (BlueDopVE)
Participants presenting for post-bypass surveillance
Device: MESI mTablet · Device: BlueDop vascular Expert (BlueDopVE)
The MESI mTablet uses 3CUFFTM technology to detect pulse waveforms to assess ABPI. This involves placing a blood pressure cuff on all 4 limbs at the same time. The two arm cuffs then inflate and simultaneously measure the blood pressure in both brachial arteries. The cuff with the highest systolic pressure than reinflates with both the ankle cuffs simultaneously. The ABPI is then calculated and displayed on the tablet. A ratio of \<0.9 will indicate the presence of PAD.
The BlueDop device is a cuffless device which comprises an egg-shaped handheld probe component and an output monitor device. The device measures mean arterial blood pressure through an algorithm. Simply, it calculates the average blood pressure based on the normal rise and fall of pressure during each heartbeat. The device then automatically generates an ankle-brachial pressure index and a corresponding traffic-light classification for each lower-limb artery, based on waveform. This output is interpreted using table 2 below. Essentially an ABPI of 0.8-1.0 with a biphasic or triphasic waveform indicates no disease whereas an ABPI \<0.8 and / or a monophasic/non-specific waveform indicates the presence of PAD.
Diagnostic Accuracy
Diagnostic accuracy assessed via sensitivity, specificity, positive predictor value (PPV) and negative predictor value (NPV).
Time frame: From enrolment to the end of treatment (1 day)
Validity assessed via correlation
Diagnostic performance assessed via area under the receiver operating characteristic (AUROC) curve and the assessment time difference, assessed via measurement of the time taken to perform each automated ABPI assessment and the manual ABPI assessment.
Time frame: Data collected at enrolment (1 day)
Diagnostic performance
Assessed via area under the receiver operating characteristic (AUROC) curve.
Time frame: Data collected at enrolment (1 day)
Time taken to perform each automated ABPI assessment and the manual ABPI assessment.
Time taken to perform each assessment in seconds
Time frame: Data collected at enrolment (1 day)
Qualitative Workstream - Assessment of usability and tolerability of automated devices.
Semi structured interviews analysed using thematic analysis
Time frame: Within the 2 year recruitment period
Visual Analogue Scale (VAS) score of 0-10
VAS used to assess tolerability
Time frame: Data collected at point of enrolment (1 day)
Started Jun 2026 (actual). Primary completion is estimated for Sep 2028, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hull University Teaching Hospitals NHS Trust